Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Izalontamab brengitecan phase 3 trial in HR+/HER2- breast cancer

PANKU-Breast01 is a randomized phase 3 trial of izalontamab brengitecan in HR+/HER2- breast cancer in China; results were not included in the scrape.

REFINE-Lung is testing reduced-frequency pembrolizumab in advanced non-small-cell lung cancer using a multi-arm phase 3 design to curb…

REDMOD detected hidden pancreatic cancer signals 475 days early and outperformed radiologists, raising hopes for earlier treatment.

Researchers built MEGA, a graph-based bioinformatics tool to identify intratumoral microbes across 2,704 tumor RNA sequencing samples from…

Germline RNF43 variants confer moderate colorectal cancer risk, with stronger effects in N-terminal mutations and distinct somatic patterns.

Large family-based analysis links CTNNA1 truncating variants to diffuse gastric cancer and lobular breast cancer, and refines testing…

OrigAMI-5 is a phase 3 randomized study comparing amivantamab plus pembrolizumab and carboplatin with standard pembrolizumab-based care in…

Single-cell and functional data link B4GALNT1-driven ganglioside remodeling to ferroptosis resistance and poorer sorafenib response in HCC.

FAHR-Face, trained on more than 40 million face photos, estimated biological age and predicted survival in cancer cohorts…

NCI is recruiting senior clinicians to lead investigator-initiated cancer trials, manage multidisciplinary teams, and build research programs at…

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds